Floatz logo

FENTANYL

Kidney Cancer

Medical University of WarsawSmall moleculePhase 4 / ApprovedDormant
B
61/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
53/ 100
Competitive Position
73/ 100

Competitive context

71 Active assets in the Kidney Cancer cohort.

Asset / SponsorPhaseRating
Alpha-Interferon
Dartmouth-Hitchcock Medical Center
Phase 3BBB
Girentuximab
Memorial Sloan Kettering Cancer Center
Phase 3BB
FILGRASTIM
National Institutes of Health Clinical Center (CC)
Phase 3BB
FLUOROURACILUM
Medical Research Council
Phase 3BB
ETOPOSIDE
City of Hope Medical Center
Phase 3BB

View all 50 →

Same molecule, other indications

FENTANYL is also rated in:

Low Back PainDormant
BBB
Indicative ·
75 / 100
View asset →
PainDormant
BBB
Indicative ·
74 / 100
View asset →
chronic pain syndromeDormant
BBB
Indicative ·
74 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →